Still haunted by its founder’s scandalous past, Kadmon scores a $75M IPO
Like a number of biotechs these days, Kadmon had to lower its price and bump up the number of shares to get its IPO done …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
